Women's Health Market

Women’s Health Market (Treatment Type: Hormonal Treatment and Non-hormonal Treatment; and Disease Indication: Cancer, Hypothyroidism, Osteoporosis, Contraception, Uterine Fibroid, Urinary Tract Infection, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Global Women’s Health Market Outlook 2031

  • The global market was valued at US$ 77.8 Bn in 2022
  • It is projected to grow at a CAGR of 5.5% from 2023 to 2031 and reach US$ 130.9 Bn by the end of 2031

Analyst Viewpoint

Increase in biological health issues is a prominent factor boosting the women's health market size. Menopausal and postmenopausal health issues severely affect women’s health and well-being. These health issues not only affect women physically, but also mentally and emotionally. Increase in elderly women population is also driving market progress. Furthermore, rise in prevalence of cervical and ovarian cancer is prompting healthcare facilities to focus on women’s health.

Rise in nutritional deficiencies among women has led dieticians and healthcare professionals to prescribe dietary supplements. Development of natural dietary supplements is likely to propel market dynamics. In line with the latest women’s health market trends, manufacturers are investing substantially in development of new products in the natural supplements portfolio to strengthen their industry share.

Global Womens Health Market

Global Women’s Health Market Introduction

Women's health encompasses physical, mental, and emotional well-being of women. Autoimmune diseases, pregnancy issues, ovarian & cervical cancer, heart disease, breast cancer, sexually transmitted diseases, and depression & anxiety are some of the critical health issues that may affect women.

Early diagnosis and treatment or management of these health conditions can help women stay healthy. Regular checkups by physicians and gynecologists are advised to detect unforeseen infections or diseases.

Maintaining a healthy diet and regular workout can help women manage health concerns such as obesity, stress, hypertension, and irregular menstrual cycle. These conditions have the potential to result in severe health issues such as urinary tract infections, ovarian cancer, heart diseases, and cervical cancer.

Increase in Biological Health Issues Fueling Women’s Health Industry Growth

Biological concerns in women differ from men. Severe complications during pregnancy, diseases specific to female organs such as ovaries and breasts, and abnormal menstruation are some of the major biological concerns that women may face. Abnormality in menstruation and urinary tract infections may be seen in women during early teenage to menopause phases.

These health concerns are rapidly increasing among women due to factors such as sedentary lifestyle, inappropriate diet, poor sleep schedule, physical inactivity, stress, and hypertension. Rise in prevalence of these concerns is driving the women’s health market growth.

Menopause is one of the critical issues among aging women. It causes several biological concerns and discomfort. According to the National Institutes of Health, the world population of menopausal and postmenopausal women is anticipated to reach 1.2 billion by 2030, with 47 million women affected each year.

Development of Supplements to Overcome Nutritional Deficiencies Boosting Market Statistics

Some of the prominent nutritional deficiencies among women include that of calcium, iron, iodine, folate, vitamin D, magnesium, omega-3, and vitamin B12. These deficiencies can lead to skin concerns, inflammation, respiratory infections, infertility, and night blindness. Rise in demand for calcium and iron supplements is fueling market development.

Companies are introducing various dietary supplements to help women overcome nutritional deficiencies. These dietary supplements include vitamin D, multivitamins, probiotics, calcium, and omega-3 fatty acids.

Inclusion of natural sources in such supplements is leading to a rise in consumer inclination toward these products. Women are increasingly opting for herbal supplements to avoid side effects caused by synthetic supplements.

Regional Outlook

As per the regional women’s health market analysis, North America is projected to hold dominant share industry across the globe. Rise in prevalence of breast cancer among women in the region has resulted in an increase in focus on women’s wellness.

Surge in awareness about cancer care among women is also likely to drive women’s health industryt value in North America in the next few years. Government and private agencies in the region are investing significantly in drug research activities to control cancer cases among women. Furthermore, rise in awareness campaigns by governments is projected to boost women’s health industry share of North America.

Analysis of Key Players in Women’s Health Industry

Leading players operating in the sector are implementing various strategies such as new drug development and mergers and acquisitions to strengthen their global footprint.

Eli Lilly and Company, Novartis AG, Pfizer, Inc., Merck & Co., Inc., Novo Nordisk A/S, Amgen Inc., AstraZeneca, F. Hoffmann-La Roche Ltd, Sanofi, Allergan Plc., GlaxoSmithKline plc, and Lupin Pharmaceuticals, Inc. are the prominent companies operating in the global landscape.

These firms have been profiled in the women’s health market report based on parameters such as recent developments, business strategies, company overview, product portfolio, business segments, and financial overview.

Key Developments

  • On November 17, 2023, AstraZeneca received U.S. Food and Drug Administration approval for Truqap, a breast cancer drug, in combination with Faslodex. It claims to reduce the risk of disease progression and death rate by 50%.
  • On June 1, 2023, Nykode announced its collaboration with F. Hoffmann-La Roche Ltd to investigate a combination treatment in patients suffering from advanced cervical cancer. The treatment will be provided by combining Nykode’s VB10.16 with Roche’s immunotherapy Tecentriq.

Women’s Health Market Snapshot

Attribute Detail
Market Size in 2022 US$ 77.8 Bn
Market Forecast (Value) in 2031 US$ 130.9 Bn
Growth Rate (CAGR) 5.5%
Forecast Period 2023-2031
Historical Data Available for 2017-2021
Quantitative Tons US$ Bn for Value
Market Analysis It includes segment analysis as well as regional level analysis. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces Analysis, value chain analysis, and key trend analysis.
Competition Landscape
  • Market share analysis by company (2022)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy and recent developments, and key financials
Format Electronic (PDF) + Excel
Market Segmentation
  • Treatment Type
    • Hormonal Treatment
      • Estrogen Therapy
      • Progestin Therapy
      • Combination Therapy
      • Thyroid Replacement Therapy
      • Parathyroid Hormone Therapy
      • Others
    • Non-hormonal Treatment
      • Targeted Therapy Drugs
      • Antibiotics
      • Bisphosphonates
      • Others
  • Disease Indication
    • Cancer
      • Breast Cancer
      • Cervical Cancer
      • Ovarian Cancer
    • Hypothyroidism
    • Post-menopausal Syndrome
    • Osteoporosis
    • Contraception
    • Uterine Fibroid
    • Urinary Tract Infection
    • Others
Regions Covered
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
Countries Covered
  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Japan
  • China
  • India
  • Brazil
  • Mexico
  • South Africa
  • GCC countries
Companies Profiled
  • Eli Lilly and Company
  • Novartis AG
  • Pfizer, Inc.
  • Merck & Co., Inc.
  • Novo Nordisk A/S
  • Amgen, Inc.
  • AstraZeneca
  • F. Hoffmann-La Roche Ltd.
  • Sanofi
  • Allergan plc
  • GlaxoSmithKline plc
  • Lupin Pharmaceuticals, Inc.
Customization Scope Available upon request
Pricing Available upon request

Frequently Asked Questions

How big was the global women’s health market in 2022?

It was valued at US$ 77.8 Bn in 2022

How is the women’s health business expected to grow by 2031?

It is projected to register a CAGR of 5.5% from 2023 to 2031

What are the key factors driving the women’s health industry?

Increase in biological health issues and development of supplements to overcome nutritional deficiencies

Which region was the most lucrative in the women’s health sector in 2022?

North America was the most lucrative region in 2022

Who are the prominent players in the women’s health landscape?

Eli Lilly and Company, Novartis AG, Pfizer, Inc., Merck & Co., Inc., Novo Nordisk A/S, Amgen Inc., AstraZeneca, F. Hoffmann-La Roche Ltd, Sanofi, Allergan Plc., GlaxoSmithKline plc, and Lupin Pharmaceuticals, Inc.

    1. Executive Summary

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Women’s Health Market

    4. Market Overview

        4.1. Market Segmentation

            4.1.1. Segment Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Women’s Health Market Analysis and Forecast, 2023-2031

    5. Key Insights

        5.1. Pipeline Analysis

        5.2. List of Common Health Issues Among Women

        5.3. Disease Prevalence & Incidence Rate Globally With Key Countries

        5.4. COVID-19 Pandemic Impact on Industry

    6. Women’s Health Market Analysis and Forecast, by Treatment Type

        6.1. Introduction and Definitions

        6.2. Key Findings/Developments

        6.3. Market Value Forecast, by Treatment Type, 2023-2031

            6.3.1. Hormonal Treatment

                6.3.1.1. Estrogen Therapy

                6.3.1.2. Progestin Therapy

                6.3.1.3. Combination Therapy

                6.3.1.4. Thyroid Replacement Therapy

                6.3.1.5. Parathyroid Hormone Therapy

                6.3.1.6. Others

            6.3.2. Non-Hormonal Treatment

                6.3.2.1. Targeted Therapy Drugs

                6.3.2.2. Antibiotics

                6.3.2.3. Bisphosphonates

                6.3.2.4. Others

        6.4. Market Attractiveness, by Treatment Type

    7. Global Women’s Health Market Analysis and Forecast, by Disease Indication

        7.1. Introduction and Definitions

        7.2. Key Findings/Developments

        7.3. Market Value Forecast, by Disease Indication, 2023-2031

            7.3.1. Cancer

                7.3.1.1. Breast Cancer

                7.3.1.2. Cervical Cancer

                7.3.1.3. Ovarian Cancer

            7.3.2. Hypothyroidism

            7.3.3. Post-Menopausal Syndrome

            7.3.4. Osteoporosis

            7.3.5. Contraception

            7.3.6. Uterine Fibroid

            7.3.7. Urinary Tract Infection

            7.3.8. Others

        7.4. Market Attractiveness, by Disease Indication

    8. Global Women’s Health Market Analysis and Forecast, by Region

        8.1. Key Findings

        8.2. Market Value Forecast, by Region, 2023-2031

            8.2.1. North America

            8.2.2. Europe

            8.2.3. Asia Pacific

            8.2.4. Latin America

            8.2.5. Middle East & Africa

        8.3. Market Attractiveness, by Region

    9. North America Women’s Health Market Analysis and Forecast

        9.1. Introduction

            9.1.1. Key Findings

        9.2. Market Value Forecast, by Treatment Type, 2023-2031

            9.2.1. Hormonal Treatment

                9.2.1.1. Estrogen Therapy

                9.2.1.2. Progestin Therapy

                9.2.1.3. Combination Therapy

                9.2.1.4. Thyroid Replacement Therapy

                9.2.1.5. Parathyroid Hormone Therapy

                9.2.1.6. Others

            9.2.2. Non-Hormonal Treatment

                9.2.2.1. Targeted Therapy Drugs

                9.2.2.2. Antibiotics

                9.2.2.3. Bisphosphonates

                9.2.2.4. Others

        9.3. Market Value Forecast, by Disease Indication, 2023-2031

            9.3.1. Cancer

                9.3.1.1. Breast Cancer

                9.3.1.2. Cervical Cancer

                9.3.1.3. Ovarian Cancer

            9.3.2. Hypothyroidism

            9.3.3. Post-Menopausal Syndrome

            9.3.4. Osteoporosis

            9.3.5. Contraception

            9.3.6. Uterine Fibroid

            9.3.7. Urinary Tract Infection

            9.3.8. Others

        9.4. Market Value Forecast, by Country, 2023-2031

            9.4.1. U.S.

            9.4.2. Canada

        9.5. Market Attractiveness Analysis

                9.5.1.1. By Treatment Type

                9.5.1.2. By Disease Indication

                9.5.1.3. By Country

    10. Europe Women’s Health Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Market Value Forecast, by Treatment Type, 2023-2031

            10.2.1. Hormonal Treatment

                10.2.1.1. Estrogen Therapy

                10.2.1.2. Progestin Therapy

                10.2.1.3. Combination Therapy

                10.2.1.4. Thyroid Replacement Therapy

                10.2.1.5. Parathyroid Hormone Therapy

                10.2.1.6. Others

            10.2.2. Non-Hormonal Treatment

                10.2.2.1. Targeted Therapy Drugs

                10.2.2.2. Antibiotics

                10.2.2.3. Bisphosphonates

                10.2.2.4. Others

        10.3. Market Value Forecast, by Disease Indication, 2023-2031

            10.3.1. Cancer

                10.3.1.1. Breast Cancer

                10.3.1.2. Cervical Cancer

                10.3.1.3. Ovarian Cancer

            10.3.2. Hypothyroidism

            10.3.3. Post-Menopausal Syndrome

            10.3.4. Osteoporosis

            10.3.5. Contraception

            10.3.6. Uterine Fibroid

            10.3.7. Urinary Tract Infection

            10.3.8. Others

        10.4. Market Value Forecast, by Country/Sub-region, 2023-2031

            10.4.1. Germany

            10.4.2. U.K.

            10.4.3. France

            10.4.4. Italy

            10.4.5. Spain

            10.4.6. Rest of Europe

        10.5. Market Attractiveness Analysis

                10.5.1.1. By Treatment Type

                10.5.1.2. By Disease Indication

                10.5.1.3. By Country/Sub-region

    11. Asia Pacific Women’s Health Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast, by Treatment Type, 2023-2031

            11.2.1. Hormonal Treatment

                11.2.1.1. Estrogen Therapy

                11.2.1.2. Progestin Therapy

                11.2.1.3. Combination Therapy

                11.2.1.4. Thyroid Replacement Therapy

                11.2.1.5. Parathyroid Hormone Therapy

                11.2.1.6. Others

            11.2.2. Non-Hormonal Treatment

                11.2.2.1. Targeted Therapy Drugs

                11.2.2.2. Antibiotics

                11.2.2.3. Bisphosphonates

                11.2.2.4. Others

        11.3. Market Value Forecast, by Disease Indication, 2023-2031

            11.3.1. Cancer

                11.3.1.1. Breast Cancer

                11.3.1.2. Cervical Cancer

                11.3.1.3. Ovarian Cancer

            11.3.2. Hypothyroidism

            11.3.3. Post-Menopausal Syndrome

            11.3.4. Osteoporosis

            11.3.5. Contraception

            11.3.6. Uterine Fibroid

            11.3.7. Urinary Tract Infection

            11.3.8. Others

        11.4. Market Value Forecast, by Country/Sub-region, 2023-2031

            11.4.1. China

            11.4.2. Japan

            11.4.3. India

            11.4.4. Australia & New Zealand

            11.4.5. Rest of Asia Pacific

        11.5. Market Attractiveness Analysis

            11.5.1. By Treatment Type

            11.5.2. By Disease Indication

            11.5.3. By Country/Sub-region

    12. Latin America Women’s Health Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast, by Treatment Type, 2023-2031

            12.2.1. Hormonal Treatment

                12.2.1.1. Estrogen Therapy

                12.2.1.2. Progestin Therapy

                12.2.1.3. Combination Therapy

                12.2.1.4. Thyroid Replacement Therapy

                12.2.1.5. Parathyroid Hormone Therapy

                12.2.1.6. Others

            12.2.2. Non-Hormonal Treatment

                12.2.2.1. Targeted Therapy Drugs

                12.2.2.2. Antibiotics

                12.2.2.3. Bisphosphonates

                12.2.2.4. Others

        12.3. Market Value Forecast, by Disease Indication, 2023-2031

            12.3.1. Cancer

                12.3.1.1. Breast Cancer

                12.3.1.2. Cervical Cancer

                12.3.1.3. Ovarian Cancer

            12.3.2. Hypothyroidism

            12.3.3. Post-Menopausal Syndrome

            12.3.4. Osteoporosis

            12.3.5. Contraception

            12.3.6. Uterine Fibroid

            12.3.7. Urinary Tract Infection

            12.3.8. Others

        12.4. Market Value Forecast, by Country/Sub-region, 2023-2031

            12.4.1. Brazil

            12.4.2. Mexico

            12.4.3. Rest of Latin America

        12.5. Market Attractiveness Analysis

            12.5.1. By Treatment Type

            12.5.2. By Disease Indication

            12.5.3. By Country/Sub-region

    13. Middle East & Africa Women’s Health Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast, by Treatment Type, 2023-2031

            13.2.1. Hormonal Treatment

                13.2.1.1. Estrogen Therapy

                13.2.1.2. Progestin Therapy

                13.2.1.3. Combination Therapy

                13.2.1.4. Thyroid Replacement Therapy

                13.2.1.5. Parathyroid Hormone Therapy

                13.2.1.6. Others

            13.2.2. Non-Hormonal Treatment

                13.2.2.1. Targeted Therapy Drugs

                13.2.2.2. Antibiotics

                13.2.2.3. Bisphosphonates

                13.2.2.4. Others

        13.3. Market Value Forecast, by Disease Indication, 2023-2031

            13.3.1. Cancer

                13.3.1.1. Breast Cancer

                13.3.1.2. Cervical Cancer

                13.3.1.3. Ovarian Cancer

            13.3.2. Hypothyroidism

            13.3.3. Post-Menopausal Syndrome

            13.3.4. Osteoporosis

            13.3.5. Contraception

            13.3.6. Uterine Fibroid

            13.3.7. Urinary Tract Infection

            13.3.8. Others

        13.4. Market Value Forecast, by Country/Sub-region, 2023-2031

            13.4.1. GCC Countries

            13.4.2. South Africa

            13.4.3. Rest of Middle East & Africa

        13.5. Market Attractiveness Analysis

            13.5.1. By Treatment Type

            13.5.2. By Disease Indication

            13.5.3. By Country/Sub-region

    14. Competition Landscape

        14.1. Market Player - Competition Matrix (By Tier and Size of Companies)

        14.2. Market Share Analysis, by Company (2022)

        14.3. Company Profiles

            14.3.1. Eli Lilly and Company

                14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.1.2. Product Portfolio

                14.3.1.3. Financial Overview

                14.3.1.4. SWOT Analysis

                14.3.1.5. Strategic Overview

            14.3.2. Novartis AG

                14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.2.2. Product Portfolio

                14.3.2.3. Financial Overview

                14.3.2.4. SWOT Analysis

                14.3.2.5. Strategic Overview

            14.3.3. Pfizer, Inc.

                14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.3.2. Product Portfolio

                14.3.3.3. Financial Overview

                14.3.3.4. SWOT Analysis

                14.3.3.5. Strategic Overview

            14.3.4. Merck & Co., Inc.

                14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.4.2. Product Portfolio

                14.3.4.3. Financial Overview

                14.3.4.4. SWOT Analysis

                14.3.4.5. Strategic Overview

            14.3.5. Novo Nordisk A/S

                14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.5.2. Product Portfolio

                14.3.5.3. Financial Overview

                14.3.5.4. SWOT Analysis

                14.3.5.5. Strategic Overview

            14.3.6. Amgen Inc.

                14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.6.2. Product Portfolio

                14.3.6.3. Financial Overview

                14.3.6.4. SWOT Analysis

                14.3.6.5. Strategic Overview

            14.3.7. AstraZeneca

                14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.7.2. Product Portfolio

                14.3.7.3. Financial Overview

                14.3.7.4. SWOT Analysis

                14.3.7.5. Strategic Overview

            14.3.8. F. Hoffmann-La Roche Ltd

                14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.8.2. Product Portfolio

                14.3.8.3. Financial Overview

                14.3.8.4. SWOT Analysis

                14.3.8.5. Strategic Overview

            14.3.9. Sanofi

                14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.9.2. Product Portfolio

                14.3.9.3. Financial Overview

                14.3.9.4. SWOT Analysis

                14.3.9.5. Strategic Overview

            14.3.10. Allergan Plc.

                14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.10.2. Product Portfolio

                14.3.10.3. Financial Overview

                14.3.10.4. SWOT Analysis

                14.3.10.5. Strategic Overview

            14.3.11. GlaxoSmithKline plc

                14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.11.2. Product Portfolio

                14.3.11.3. Financial Overview

                14.3.11.4. SWOT Analysis

                14.3.11.5. Strategic Overview

            14.3.12. Lupin Pharmaceuticals, Inc.

                14.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.12.2. Product Portfolio

                14.3.12.3. Financial Overview

                14.3.12.4. SWOT Analysis

                14.3.12.5. Strategic Overview

    List of Tables

    Table 01: Global Women’s Health Market Value (US$ Mn) Forecast, by Treatment Type, 2023-2031

    Table 02: Global Women’s Health Market Value (US$ Mn) Forecast, by Disease Indication, 2023-2031

    Table 03: Global Women’s Health Market Value (US$ Mn) Forecast, by Region, 2023-2031

    Table 04: North America Women’s Health Market Value (US$ Mn) Forecast, by Country, 2023-2031

    Table 05: North America Women’s Health Market Value (US$ Mn) Forecast, by Treatment Type, 2023-2031

    Table 06: North America Women’s Health Market Value (US$ Mn) Forecast, by Disease Indication, 2023-2031

    Table 07: Europe Women’s Health Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023-2031

    Table 08: Europe Women’s Health Market Value (US$ Mn) Forecast, by Treatment Type, 2023-2031

    Table 09: Europe Women’s Health Market Value (US$ Mn) Forecast, by Disease Indication 2023-2031

    Table 10: Asia Pacific Women’s Health Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023-2031

    Table 11: Asia Pacific Women’s Health Market Value (US$ Mn) Forecast, by Treatment Type, 2023-2031

    Table 12: Asia Pacific Women’s Health Market Value (US$ Mn) Forecast, by Disease Indication, 2023-2031

    Table 13: Latin America Women’s Health Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023-2031

    Table 14: Latin America Women’s Health Market Value (US$ Mn) Forecast, by Treatment Type, 2023-2031

    Table 15: Latin America Women’s Health Market Value (US$ Mn) Forecast, by Disease Indication 2023-2031

    Table 16: Middle East & Africa Women’s Health Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023-2031

    Table 17: Middle East & Africa Women’s Health Market Value (US$ Mn) Forecast, by Treatment Type, 2023-2031

    Table 18: Middle East & Africa Women’s Health Market Value (US$ Mn) Forecast, by Disease Indication 2023-2031

    List of Figures

    Figure 01: Global Women’s Health Market Value (US$ Mn) Forecast, 2023-2031

    Figure 02: Global Women’s Health Market Value Share, by Treatment Type, 2022

    Figure 03: Global Women’s Health Market Value Share, by Disease Indication, 2022

    Figure 04: Global Women’s Health Market Value Share Analysis, by Treatment Type, 2022 and 2031

    Figure 05: Global Women’s Health Market Attractiveness Analysis, by Treatment Type, 2023-2031

    Figure 06: Global Women’s Health Market Value Share Analysis, by Disease Indication, 2022 and 2031

    Figure 07: Global Women’s Health Market Attractiveness Analysis, by Disease Indication 2023-2031

    Figure 08: Global Women’s Health Market Value Share Analysis, by Region, 2022 and 2031

    Figure 09: Global Women’s Health Market Attractiveness Analysis, by Region, 2023-2031

    Figure 10: North America Women’s Health Market Value (US$ Mn) Forecast, 2023-2031

    Figure 11: North America Women’s Health Market Value Share Analysis, by Country, 2022 and 2031

    Figure 12: North America Women’s Health Market Attractiveness Analysis, by Country, 2023-2031

    Figure 13: North America Women’s Health Market Value Share Analysis, by Treatment Type, 2022 and 2031

    Figure 14: North America Women’s Health Market Attractiveness Analysis, by Treatment Type, 2023-2031

    Figure 15: North America Women’s Health Market Value Share Analysis, by Disease Indication, 2022 and 2031

    Figure 16: North America Women’s Health Market Attractiveness Analysis, by Disease Indication 2023-2031

    Figure 17: Europe Women’s Health Market Value (US$ Mn) Forecast, 2023-2031

    Figure 18: Europe Women’s Health Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 19: Europe Women’s Health Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 20: Europe Women’s Health Market Value Share Analysis, by Treatment Type, 2022 and 2031

    Figure 21: Europe America Women’s Health Market Attractiveness Analysis, by Treatment Type, 2023-2031

    Figure 22: Europe Women’s Health Market Value Share Analysis, by Disease Indication, 2022 and 2031

    Figure 23: Europe Women’s Health Market Attractiveness Analysis, by Disease Indication 2023-2031

    Figure 24: Asia Pacific Women’s Health Market Value (US$ Mn) Forecast, 2023-2031

    Figure 25: Asia Pacific Women’s Health Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 26: Asia Pacific Women’s Health Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 27: Asia Pacific Women’s Health Market Value Share Analysis, by Treatment Type, 2022 and 2031

    Figure 28: Asia Pacific America Women’s Health Market Attractiveness Analysis, by Treatment Type, 2023-2031

    Figure 29: Asia Pacific Women’s Health Market Value Share Analysis, by Disease Indication, 2022 and 2031

    Figure 30: Asia Pacific Women’s Health Market Attractiveness Analysis, by Disease Indication 2023-2031

    Figure 31: Latin America Women’s Health Market Value (US$ Mn) Forecast, 2023-2031

    Figure 32: Latin America Women’s Health Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 33: Latin America Women’s Health Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 34: Latin America Women’s Health Market Value Share Analysis, by Treatment Type, 2022 and 2031

    Figure 35: Latin America Women’s Health Market Attractiveness Analysis, by Treatment Type, 2023-2031

    Figure 36: Middle East & Africa Women’s Health Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

    Figure 37: Middle East & Africa Women’s Health Market Attractiveness Analysis, by Country/Sub-region, 2023-2031

    Figure 38: Middle East & Africa America Women’s Health Market Value Share Analysis, by Treatment Type, 2023-2031

    Figure 39: Middle East & Africa America Women’s Health Market Attractiveness Analysis, by Treatment Type, 2023-2031

    Figure 40: Middle East & Africa Women’s Health Market Value Share Analysis, by Disease Indication, 2022 and 2031

    Figure 41: Middle East & Africa Women’s Health Market Attractiveness Analysis, by Disease Indication 2023-2031

    Figure 42: Global Women’s Health Market Share Analysis, by Company (2022)

Copyright © Transparency Market Research, Inc. All Rights reserved